[Successful treatment of splenic lymphoma with villous lymphocytes by rituximab and laparoscopic splenectomy].
We report on a case of splenic lymphoma with villous lymphocytes (SLVL) which responded well to rituximab. A 50-year-old man was admitted because of splenomegaly. Abnormal lymphocytes of B cell lineage with moderately basophilic cytoplasm and unevenly distributed villi (villous cells) were found, both in the peripheral blood and bone marrow. CHOP and CHOP-E were performed, without any remarkable change in the size of the spleen. However, after infusion of rituximab (375 mg/m2, once weekly for 2 weeks), there was a marked reduction of the spleen size and the number of circulating villous cells. Splenectomy was performed afterwards, followed by 2 cycles of rituximab infusion. The patient is now followed on an outpatient basis without any sign of relapse.
Fujita
Tomoko
T
Department of Internal Medicine, Sumitomo Hospital.
Asagoe
Kohsuke
K
Sakoda
Hiroto
H
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000473:pathology / Q000648:ultrastructure; D003131:Combined Modality Therapy; D006801:Humans; D010535:Laparoscopy; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D008871:Microvilli; D008875:Middle Aged; D000069283:Rituximab; D013154:Spleen / Q000166:cytology / Q000473:pathology; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab